WHO WE ARE
Every patient matters
Our pipeline contains novel therapies designed to address debilitating central nervous system (CNS) disorders in order to improve quality of life and patient outcomes.
We partner with patients, families and caregivers, and healthcare professionals to provide a comprehensive approach beyond treating symptoms to ensure that patients’ experiences, perspectives, needs, and priorities are meaningfully incorporated into our work.
A History of Success
Our leadership team has extensive experience with global biotech and pharmaceutical companies and a proven track record of developing and commercializing treatments for central nervous system (CNS) disorders.
The Noema Team
Luigi Costa
Chief Executive Officer
George Garibaldi MD
President Research & Development
Mike Gutch, Ph.D.
Chief Financial Officer
Sally Nixon
Head of Operations
Renata Lazarova, MD
VP Clinical Development, Pediatric Programs
Amine Tahiri PharmD, MBA
VP Clinical Development, Adult Programs
Simon Roitt, Ph.D.
VP, Head of Clinical Operations
Smiljana Milosavljevic Ristic MD, Ph.D.
VP Clinical Development, Behavioral Medicine Programs
Sally Barennes , Ph.D., MBA
VP Pharma Research & Development Strategy
Michel David
VP CMC & Clinical Supply
Jessica Kardish
Global Head of Clinical and Regulatory Operations
Rachel Gurrell
Head of Research and Early Development
